Genetically engineered bacteria as inflammatory bowel disease therapeutics
Engineering Microbiology · 2024-12 · 4 (4) · 100167
DOI: 10.1016/j.engmic.2024.100167 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Engineering Microbiology, 2024-12. Verfasst von Zhen-Ping Zou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai…. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic and recurrent disease caused by immune response disorders that disrupt the intestinal lumen symbiotic ecosystem and dysregulate mucosal immune functions. Current therapies available for IBD primarily focus on symptom management, making early diagnosis and prompt intervention challenging. The development of genetically engineered bacteria using synthetic biology presents a new strategy for addressing these challenges. In this review, we present recent breakthroughs in the field of engineered bacteria for the treatment and detection of IBD and describe how bacteria can be genetically modified to produce therapeutic molecules or execute diagnostic functions. In particular, we discuss the challenges faced in translating live bacterial therapeutics from bacterial design to delivery strategies for further clinical applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China
Zitieren
APA
Zou, Z. P., Zhang, X. P., Zhang, Q., Yin, B. C., Zhou, Y., & Ye, B. C. (2024). Genetically engineered bacteria as inflammatory bowel disease therapeutics. Engineering Microbiology, 4(4), 100167. https://doi.org/10.1016/j.engmic.2024.100167
Vancouver
Zou ZP, Zhang XP, Zhang Q, Yin BC, Zhou Y, Ye BC. Genetically engineered bacteria as inflammatory bowel disease therapeutics. Engineering Microbiology. 2024;4(4):100167. doi:10.1016/j.engmic.2024.100167
BibTeX
@article{Zou2024,
author = {Zou, Zhen-Ping and Zhang, Xiao-Peng and Zhang, Qian and Yin, Bin-Cheng and Zhou, Ying and Ye, Bang-Ce},
title = {Genetically engineered bacteria as inflammatory bowel disease therapeutics},
journal = {Engineering Microbiology},
year = {2024},
volume = {4},
number = {4},
pages = {100167},
doi = {10.1016/j.engmic.2024.100167}
}
EUVIMED